K Look

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi request reprint Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study
    Montaser Shaheen
    Section of Hematology Oncology, Walther Cancer Institute, Indiana University Medical Center, Indianapolis, Indiana, USA
    Am J Clin Oncol 27:229-31. 2004
  2. ncbi request reprint Carcinoma of the vulva
    Frederick B Stehman
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Obstet Gynecol 107:719-33. 2006
  3. ncbi request reprint Detection of endometrial adenocarcinoma in two asymptomatic postmenopausal women receiving tamoxifen. A report of two cases
    K Look
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis 46202, USA
    J Reprod Med 44:977-80. 1999
  4. ncbi request reprint Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
    Katherine Y Look
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:93-100. 2004
  5. ncbi request reprint Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study
    Achilles J Fakiris
    Indiana University School of Medicine, 535 Barnhill Drive, RT 041 Indianapolis, IN 46202 5289, USA
    Gynecol Oncol 96:818-23. 2005
  6. doi request reprint Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience
    Achilles J Fakiris
    Department of Radiation Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Brachytherapy 9:61-5. 2010
  7. ncbi request reprint Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study
    Katherine Y Look
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:644-7. 2004
  8. ncbi request reprint Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study
    Howard D Homesley
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brody School of Medicine, 272 Leo Jenkins Cancer Center, Greenville, NC 27858, USA
    Gynecol Oncol 98:294-8. 2005
  9. ncbi request reprint A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study
    Deborah K Armstrong
    Sidney Kimmal Comprehensive Cancer Centèr John Hopkins, Baltimore, MD 21231, USA
    Invest New Drugs 21:373-7. 2003
  10. ncbi request reprint Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study
    George A Omura
    University of Alabama at Birmingham, Birmingham, AL, USA
    J Clin Oncol 21:2843-8. 2003

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study
    Montaser Shaheen
    Section of Hematology Oncology, Walther Cancer Institute, Indiana University Medical Center, Indianapolis, Indiana, USA
    Am J Clin Oncol 27:229-31. 2004
    ..The 1-year survival probability using Kaplan-Meier analysis was 0.8. In this small sample-size trial, we did not demonstrate an advantage to this combination regimen compared to these or other single agents...
  2. ncbi request reprint Carcinoma of the vulva
    Frederick B Stehman
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Obstet Gynecol 107:719-33. 2006
    ..Adequately powered trials aimed at further reducing morbidity without compromising survival are underway...
  3. ncbi request reprint Detection of endometrial adenocarcinoma in two asymptomatic postmenopausal women receiving tamoxifen. A report of two cases
    K Look
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis 46202, USA
    J Reprod Med 44:977-80. 1999
    ..The majority of these carcinomas present with postmenopausal bleeding. The current standard is to undertake sampling only after the onset of bleeding...
  4. ncbi request reprint Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
    Katherine Y Look
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:93-100. 2004
    ....
  5. ncbi request reprint Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study
    Achilles J Fakiris
    Indiana University School of Medicine, 535 Barnhill Drive, RT 041 Indianapolis, IN 46202 5289, USA
    Gynecol Oncol 96:818-23. 2005
    ....
  6. doi request reprint Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience
    Achilles J Fakiris
    Department of Radiation Oncology, Indiana University Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Brachytherapy 9:61-5. 2010
    ....
  7. ncbi request reprint Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study
    Katherine Y Look
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Gynecol Oncol 92:644-7. 2004
    ..To determine the antitumor activity and toxicity profile of gemcitabine as second-line chemotherapy in patients with recurrent or persistent uterine leiomyosarcoma (LMS)...
  8. ncbi request reprint Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study
    Howard D Homesley
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brody School of Medicine, 272 Leo Jenkins Cancer Center, Greenville, NC 27858, USA
    Gynecol Oncol 98:294-8. 2005
    ..P., Raritan, NJ) in first-line therapy of patients with disseminated endometrial carcinoma...
  9. ncbi request reprint A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study
    Deborah K Armstrong
    Sidney Kimmal Comprehensive Cancer Centèr John Hopkins, Baltimore, MD 21231, USA
    Invest New Drugs 21:373-7. 2003
    ....
  10. ncbi request reprint Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study
    George A Omura
    University of Alabama at Birmingham, Birmingham, AL, USA
    J Clin Oncol 21:2843-8. 2003
    ....
  11. ncbi request reprint Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study
    Agustin A Garcia
    Division of Medical Oncology, University of Southern California Norrris Comprehensive Cancer Center, Los Angeles 90089, USA
    Invest New Drugs 20:383-7. 2002
    ..This, combined with preclinical synergism, prompted the Gynecologic Oncology Group to determine the maximum tolerated dose (MTD) of this combination...
  12. ncbi request reprint Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study
    Jeffrey Bell
    Ohio State University and Division of Gynecologic Oncology, Riverside Methodist Hospital Columbus Cancer Council, Columbus, OH 43214, USA
    Gynecol Oncol 102:432-9. 2006
    ....
  13. ncbi request reprint Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study
    J Tate Thigpen
    Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216 4505, USA
    Gynecol Oncol 93:336-9. 2004
    ..The Gynecologic Oncology Group (GOG) initiated a concerted effort to study cytotoxic therapy for these cancers in 1976. This report presents data on cisplatin, the first of the agents to be studied in this disease...
  14. ncbi request reprint Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study
    Gini F Fleming
    Gynecologic Oncology Group, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103, USA
    J Clin Oncol 22:2159-66. 2004
    ..Secondary comparisons included progression-free survival (PFS), response rate (RR), and toxicities...